Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Camille Lecoffre-Bernard1, Camille de Brauer2, Zoé Uhry3

  • 1Direction des maladies non transmissibles et traumatismes, Santé publique France, Saint-Maurice.

Sante Publique (Vandoeuvre-Les-Nancy, France)
|June 23, 2025
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Are pediatric central nervous system tumors on the rise in France? A population-based 21-year retrospective study.

Cancer epidemiology·2026
Same author

Impact of the French ENDOCAN-COMETE Network on Overall Survival in Rare Adrenocortical Carcinomas.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Assessing the Diagnostic Performance of a Smart Bra Using Temperature and Bioimpedance for Breast Cancer Detection: A First-in-Human Study.

Sensors (Basel, Switzerland)·2026
Same author

Early-Onset Metastatic Colorectal Adenocarcinoma Incidence and Survival Among Patients Younger Than 50 Years.

JAMA network open·2026
Same author

Corrigendum to "Combination of CDX2H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer" [In European Journal of Cancer, Volume 172, 2022, Pages 221-230, ISSN 0959-8049].

European journal of cancer (Oxford, England : 1990)·2026
Same author

Circulating levels of insulin-like growth factor I (IGF-I) and risk of multiple myeloma: An observational and Mendelian randomisation study.

British journal of haematology·2026

The 2014-2019 French Cancer program enhanced cancer surveillance by providing national incidence and survival estimates for 70 cancers. This data improves public health policies and cancer patient support.

Area of Science:

  • Epidemiology
  • Public Health

Context:

  • Cancer surveillance in France relies on a multi-source system.
  • The French network of cancer registries (Francim) collaborates with national health agencies.
  • This report details the outcomes of the 2014-2019 Cancer program.

Purpose:

  • To present the results of the 2014-2019 French Cancer program.
  • To provide updated national and district-level cancer incidence and survival estimates.
  • To analyze cancer stage at diagnosis and social disparities.

Summary:

  • The program generated incidence and survival estimates for 70 cancer types, including age-specific trends and district-level data.
  • Analysis included cancer stage distribution and social inequalities in incidence and survival.
  • Conditional net survival analysis refined the assessment of cancer mortality risk.
Keywords:
France.chronic disease indicatorsepidemiological monitoringneoplasmspublic health surveillance/methodsregistries

Related Experiment Videos

Impact:

  • The program's data informs national and regional public health policies.
  • Findings contribute to improved insurance access and a 'right to be forgotten' for cancer survivors.
  • This work supports the French cancer control Strategy 2021-2030, though challenges like registry sustainability remain.